RE: Huge potential18 Apr 2020 00:19
Shares tightly held over 70%.
Extracts from the prospectus on the last fundraiser:-
The Company anticipates that the approximate timing of results from its current programmes will be as follows:
• Blautix® Phase II interim analysis in Q2 2020;
• MRx0518 Phase I/II combination study with Keytruda®, safety and initial efficacy data from Part A in 12 patients in Q2 2020; and
• Blautix® Phase II top line results from all study subjects (expected to be approximately over 300 patients) in Q3 2020.
In order to realise value in our original gastrointestinal and auto-immune programmes the Company intends to seek partnerships to facilitate further development. With the upcoming data readouts from the Phase II study of Blautix® in IBS, the Company is actively working with potential partners with whom the Company could enter into a licensing transaction pursuant to which the partner would lead the global development and commercialisation of Blautix®, with the Company providing support to the clinical and manufacturing functions.
Our work in asthma and neurodegeneration are both examples where the Directors believe the Company’s live biotherapeutics approach has the potential to address significant unmet clinical needs. Asthma is a disease in which there has been little development in terms of new therapies in recent years, and there are still significant numbers of patients who are unable to effectively control their disease. Through our MicroRx® platform, the Company was able to identify a novel LBP that can address both neutrophilic and eosinophilic lung inflammation concurrently – something not possible with existing approved asthma therapies. This programme is now in a Phase I/II trial from which top line clinical data is expected in Q4 2020.
Sign In
Follow the stocks
